Mike joined TopiVert as Head of Clinical Development in August 2014 to lead TopiVert’s innovative clinical research programmes, including the TOP1288 Phase 1 study and proof of concept study in ulcerative colitis.   Mike has over 25 years of experience in the pharmaceutical industry having held roles of increasing responsibility leading successful drug development strategies from First in Human clinical trials to marketing authorisation. He was previously Managing Director of Sunovion Europe, the London based drug development subsidiary of a top 10 Japanese pharmaceutical company and prior to that was Head of Clinical Operations at Astra UK. He has a Pharmacology PhD from the University of London and a Certificate in Company Direction awarded by the Institute of Directors. Mike joined TopiVert as Head of Clinical Development in August 2014 to lead TopiVert’s innovative clinical research programmes, including the TOP1288 Phase 1 study and proof of concept study in ulcerative colitis.   Mike has over 25 years of experience in the pharmaceutical industry having held roles of increasing responsibility leading successful drug development strategies from First in Human clinical trials to marketing authorisation. He was previously Managing Director of Sunovion Europe, the London based drug development subsidiary of a top 10 Japanese pharmaceutical company and prior to that was Head of Clinical Operations at Astra UK. He has a Pharmacology PhD from the University of London and a Certificate in Company Direction awarded by the Institute of Directors.

fermentation